{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:06:11Z","timestamp":1649192771835},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0131565","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T18:18:23Z","timestamp":1438193903000},"page":"e0131565","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov - NCT02247141)"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02247141","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Clive","family":"Dash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernie","family":"Gascoigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Gillanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hock","family":"Gooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/bmj.308.6928.581","article-title":"Consensus on diagnosis and management of primary antibody deficiencies","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2249.2007.03432.x","article-title":"Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review","volume":"149","author":"P Wood","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"ref3","first-page":"108","article-title":"Subcutaneous administration of immunoglobulins. What are the advantages?","volume":"6","author":"A Gardulf","year":"1996","journal-title":"Clin Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","article-title":"Subcutaneous immunoglobulin replacement in primary immunodeficiencies","volume":"112","author":"M Berger","year":"2004","journal-title":"Clin Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in threatment of primary antibody deficiencies:systematic review and meta analysis","volume":"32","author":"H Abolhassani","year":"2012","journal-title":"J Clini Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"U Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"A Gardulf","year":"2004","journal-title":"J Allergy Clin Immunology"},{"key":"ref8","unstructured":"CPMP Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG) (2000). CPMP\/BPWG\/388\/95, revision 1. London."},{"key":"ref9","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1996). ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice: E6(R1)."},{"issue":"Suppl. 1","key":"ref10","first-page":"1","article-title":"Primary immunodeficiency diseases","volume":"109","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"ref11","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994). ICH Harmonised Tripartite Guideline. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting: E2A."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/adc.79.1.48","article-title":"Immunoglobulin replacement treatment by rapid subcutaneous infusion","volume":"79","author":"J Gaspar","year":"1998","journal-title":"Arch Dis Child"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"HM Chapel","year":"2000","journal-title":"J Clin Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2014a prospective, multi-national study","volume":"26","author":"A Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10875-010-9417-2","article-title":"Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels","volume":"30","author":"S Th\u00e9pot","year":"2010","journal-title":"J Clin Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"M Berger","year":"2011","journal-title":"Clin Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/ACI.0b013e32834c22da","article-title":"Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose","volume":"11","author":"M Berger","year":"2011","journal-title":"Current Opinion in Allergy and Clinical Immunology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10875-011-9512-z","article-title":"Efficacy, safety and pharmacokinetics of a 10% liquid immuneglobulin preparation (Gammagard Liquid, 10%) administered subcutaneously in patients with primary immunodeficiency disease","volume":"31","author":"RL Wasserman","year":"2011","journal-title":"J Clin Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2249.2010.04195.x","article-title":"Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate\/chromatography purified in patients with primary immunodeficiency disease","volume":"161","author":"RL Wasserman","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"HD Ochs","year":"2006","journal-title":"J Clin Immunol"},{"issue":"Suppl 2","key":"ref21","doi-asserted-by":"crossref","first-page":"s108","DOI":"10.1016\/j.jaci.2005.12.432","article-title":"Percentage of patients experiencing local infusion-site reactions during subcutaneous immunoglobulin therapy decreases rapidly upon repeated infusions","volume":"117","author":"MR Stein","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"ref22","first-page":"1","article-title":"Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency","volume":"4","author":"A Gardulf","year":"1993","journal-title":"Immunodeficiency"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0131565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T15:25:02Z","timestamp":1540221902000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0131565"}},"subtitle":[],"editor":[{"given":"Toby M","family":"Maher","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,29]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0131565","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,29]]}}}